{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:28:09Z","timestamp":1789111689287,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"am","delay-in-days":336,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21ak0101171"],"award-info":[{"award-number":["JP21ak0101171"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.bbrc.2025.151420","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T18:52:27Z","timestamp":1738090347000},"page":"151420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Enhanced oral insulin delivery with charge-reversible lipid nanoparticles"],"prefix":"10.1016","volume":"750","author":[{"given":"Dai","family":"Oyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuki","family":"Matayoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soya","family":"Kanetaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiori","family":"Nitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1763-6593","authenticated-orcid":false,"given":"Hiroyuki","family":"Koide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4867-9361","authenticated-orcid":false,"given":"Keiko","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Asai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.bbrc.2025.151420_bib1","first-page":"818","article-title":"Future prospects for clinical development of oral GLP-1 and insulin formulations","volume":"61","author":"Takeda-Morishita","year":"2018","journal-title":"J. Jpn. Diabetes Soc."},{"issue":"5","key":"10.1016\/j.bbrc.2025.151420_bib2","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1248\/bpb.b17-00951","article-title":"Combination strategy with Complexation hydrogels and cell-penetrating peptides for oral delivery of insulin","volume":"41","author":"Fukuoka","year":"2018","journal-title":"Biol. Pharmaceut. Bull."},{"key":"10.1016\/j.bbrc.2025.151420_bib3","first-page":"392","article-title":"Advances in oral peptide drug nanoparticles for diabetes mellitus treatment","volume":"15","author":"Li","year":"2022","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.bbrc.2025.151420_bib4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12951-015-0136-y","article-title":"Nanoparticle based insulin delivery system: the next generation efficient therapy for Type 1 diabetes","volume":"13","author":"Sharma","year":"2015","journal-title":"J. Nanobiotechnol."},{"issue":"2","key":"10.1016\/j.bbrc.2025.151420_bib5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1507\/endocrj1954.28.235","article-title":"No reduction of blood glucose in diabetic rats after oral administration of insulin liposomes prepared under acidic conditions","volume":"28","author":"Kawada","year":"1981","journal-title":"Endocrinol. Jpn."},{"issue":"8","key":"10.1016\/j.bbrc.2025.151420_bib6","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.xphs.2018.04.011","article-title":"Bioadhesive chitosan-coated cationic nanoliposomes with improved insulin encapsulation and prolonged oral hypoglycemic effect in diabetic mice","volume":"107","author":"Shalaby","year":"2018","journal-title":"J. Pharmaceut. Sci."},{"issue":"3","key":"10.1016\/j.bbrc.2025.151420_bib7","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3390\/pharmaceutics15030820","article-title":"pH-responsive and mucoadhesive nanoparticles for enhanced oral insulin delivery: the effect of hyaluronic acid with different molecular weights","volume":"15","author":"Wang","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbrc.2025.151420_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119479","article-title":"Charge-reversible lipid derivative: a novel type of pH-responsive lipid for nanoparticle-mediated siRNA delivery","volume":"585","author":"Hirai","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.bbrc.2025.151420_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-99180-5","article-title":"Cytosolic protein delivery using pH-responsive, charge-reversible lipid nanoparticles","volume":"11","author":"Hirai","year":"2021","journal-title":"Sci. Rep."},{"issue":"1\u20132","key":"10.1016\/j.bbrc.2025.151420_bib10","first-page":"212","article-title":"Effective protection and controlled release of insulin by cationic beta-cyclodextrin polymers from alginate\/chitosan nanoparticles","volume":"393","author":"Zhang","year":"2010","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.bbrc.2025.151420_bib11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1248\/bpb.16.457","article-title":"Influence of liposomes on tryptic digestion of insulin","volume":"16","author":"Kato","year":"1993","journal-title":"Biol. Pharmaceut. Bull."},{"issue":"11","key":"10.1016\/j.bbrc.2025.151420_bib12","doi-asserted-by":"crossref","first-page":"9315","DOI":"10.1021\/acsami.8b00507","article-title":"Novel solid lipid nanoparticle with endosomal escape function for oral delivery of insulin","volume":"10","author":"Xu","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"1","key":"10.1016\/j.bbrc.2025.151420_bib13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0378-5173(97)00237-8","article-title":"Oral delivery of insulin by using surface coating liposomes: improvement of stability of insulin in GI tract","volume":"157","author":"Iwanaga","year":"1997","journal-title":"Int. J. Pharm."},{"issue":"6","key":"10.1016\/j.bbrc.2025.151420_bib14","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1248\/bpb.b19-00032","article-title":"Design of a novel PEGylated liposomal vector for systemic delivery of siRNA to solid tumors","volume":"42","author":"Song","year":"2019","journal-title":"Biol. Pharmaceut. Bull."},{"issue":"4","key":"10.1016\/j.bbrc.2025.151420_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.78","article-title":"Streptozotocin-induced diabetic models in mice and rats","volume":"1","author":"Furman","year":"2021","journal-title":"Current protocols"},{"issue":"5","key":"10.1016\/j.bbrc.2025.151420_bib16","first-page":"379","article-title":"Committee statement on diagnostic criteria for diabetes mellitus in animal models","volume":"53","author":"Yagihashi","year":"2010","journal-title":"J. Jpn. Diabetes Soc."},{"issue":"5","key":"10.1016\/j.bbrc.2025.151420_bib17","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1021\/acs.cgd.1c01463","article-title":"Unraveling the impact of pH on the crystallization of pharmaceutical proteins: a case study of human insulin","volume":"22","author":"Link","year":"2022","journal-title":"Cryst. Growth Des."},{"issue":"5","key":"10.1016\/j.bbrc.2025.151420_bib18","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s11095-010-0349-6","article-title":"Influence of acylation on the adsorption of insulin to hydrophobic surfaces","volume":"28","author":"Pinholt","year":"2011","journal-title":"Pharmaceut. Res."},{"issue":"3","key":"10.1016\/j.bbrc.2025.151420_bib19","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1248\/cpb.48.325","article-title":"High entrapment of insulin and bovine serum albumin into neutral and positively-charged liposomes by the remote loading method","volume":"48","author":"Hwang","year":"2000","journal-title":"Chem. Pharmaceut. Bull."},{"key":"10.1016\/j.bbrc.2025.151420_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119516","article-title":"Prediction of the enhanced insulin absorption across a triple co-cultured intestinal model using mucus penetrating PLGA nanoparticles","volume":"585","author":"Jaradat","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.bbrc.2025.151420_bib21","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3390\/pharmaceutics15030772","article-title":"Recent progress of lipid nanoparticles-based lipophilic drug delivery: focus on surface modifications","volume":"15","author":"Seo","year":"2023","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.bbrc.2025.151420_bib22","first-page":"743","article-title":"Pharmacoepidemiological study on the incidence of hypoglycemia during drug therapy for diabetes","volume":"49","author":"Hayashi","year":"2006","journal-title":"J. Jpn. Diabetes Soc."},{"issue":"Pt A","key":"10.1016\/j.bbrc.2025.151420_bib23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug Deliv. Rev."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25001342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25001342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T16:54:33Z","timestamp":1750092873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X25001342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":23,"alternative-id":["S0006291X25001342"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.151420","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced oral insulin delivery with charge-reversible lipid nanoparticles","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.151420","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"151420"}}